黄诗纯 沈琰 詹明

    【摘要】 糖尿病肾病(diabetic kidney disease，DKD)是糖尿病的一个主要微血管并发症和发生终末期肾病的主要原因。目前血肌酐和尿微量白蛋白等临床指标是评估DKD患者肾组织损伤程度和肾功能进展的主要依据，但其仍具有较大的局限性，尤其对于部分早期DKD患者不敏感。因此，亟须寻找拥有较高准确性的诊断及判断预后的生物标志物。近期系列研究表明一些特异性分子可作为新型生物标志物用于早期诊断DKD、监测其进展以及判断预后，如肾损伤分子-1、半胱氨酸蛋白酶抑制剂C和肌醇加氧酶等。这些分子通过特异性反映肾小管细胞损伤进而揭示早期肾组织结构损伤与功能异常，敏感性甚至优于尿微量白蛋白。本文就近年来肾小管损伤的诊断标志物在DKD中的研究新进展同时结合笔者自身的研究工作做如下综述。

    【关键词】 糖尿病肾病 肾小管损伤 生物标志物

    Research Progress on the Tubular Injury Diagnostic Biomarkers of Diabetic Kidney Disease/HUANG Shichun， SHEN Yan， ZHAN Ming. //Medical Innovation of China， 2021， 18(10)： -177

    [Abstract] Diabetic kidney disease (DKD) is one of the complications of microvascular complication in diabetes as well as a leading cause of end-stage renal disease. Now serum creatinine， microalbuminuria and other clinical indicators are regarded as main basis for evaluating the degree of renal tissue damage and renal function progression in patients with DKD， but they still have great limitations， especially insensitive to some patients with early DKD. Thus， it is urgent to find novel biomarkers with higher accuracy for diagnosis and prognosis. Recent studies have shown that some specific molecules can be used as novel biomarkers for early diagnosis of DKD and prediction of disease progress and prognosis ......